Home
Disease Knowledge Center Drug Hub Monographs Drug Interactions Pregnancy Drug Safety Drug Recalls & Alerts OTC Navigator
Virtual Simulators Hub Clinical Cases Simulator Nutrition & Macro Calculator
Questo Insights Global Opportunities Hub AI Research Assistant Citation & Reference Generator Scholarships & Essay Planner Visa & Mobility Navigator English Assessment Test
Verified Jobs Board Pharmacy Clearance Pharmacies Directory
Practice Quizzes STEM Academy Toolkits
Medical Case Donations Opportunity Crowdfunding Community Forums Courses Academy
Back to Safety Checker

Valproic Acid

Anticonvulsant & Mood Stabilizer

FDA Category D (Epilepsy) / FDA Category X (Migraine Prophylaxis) FDA Category D/X & Black Box Warning
Contraindicated — Black Box Neural Tube Defects & Lower IQ

Valproic acid (Depakote) is one of the highest-risk teratogenic anticonvulsants. Causes major congenital malformations in 10% of exposed fetuses (neural tube defects / spina bifida, facial clefts, cardiovascular defects) and permanent cognitive impairment (decreased IQ by 8–11 points, autism spectrum disorders).

Medical Disclaimer: This report is for educational and informational purposes only. It does not replace professional medical advice. Always consult your healthcare provider before making any medication decisions during pregnancy.
Pregnancy Summary
Clinical overview for pregnancy

FDA Black Box Warning: Valproate is contraindicated for migraine prophylaxis in pregnant women and strongly avoided for epilepsy/bipolar unless no alternative exists.

Trimester Safety Timeline
Safety profile across all three trimesters
1st Trimester
Weeks 1 – 12
Contraindicated

10-fold increase in neural tube defects (spina bifida).

2nd Trimester
Weeks 13 – 27
Contraindicated

Causes neurodevelopmental damage and decreased child IQ.

3rd Trimester
Weeks 28 – Birth
Contraindicated

Neonatal withdrawal and bleeding diathesis.

Placental Transfer
Does this medication cross the placenta?
Crosses Placenta
Yes
Transfer Extent
High (Umbilical cord levels higher than maternal levels)

Accumulates in fetal blood, impairing folate metabolism and histone deacetylase function.

Fetal Risk Assessment
Potential effects on the developing fetus
Fetal Valproate Syndrome & Spina Bifida

Spina bifida, craniofacial defects, cardiovascular anomalies, and limb defects.

Neurodevelopmental Deficits & Decreased IQ

Dose-dependent decrease in child IQ (8-11 points) and 3- to 5-fold increase in Autism Spectrum Disorders.

Maternal Risk Assessment
Potential maternal side effects during pregnancy
Hepatotoxicity & Pancreatitis

Black Box warnings for fatal hepatic failure and pancreatitis.

Clinical Recommendation
Professional prescribing guidance
Avoid — Transition to Lamotrigine or Levetiracetam

Avoid valproate in women of childbearing potential. Transition to safer anticonvulsants (lamotrigine or levetiracetam) prior to conception.

If Already Taken
"I took this before knowing I was pregnant"
1
Consult Neurologist Immediately

Do not stop abruptly to avoid status epilepticus. Contact your neurologist and OB/GYN urgently to plan a safe transition.

Pregnancy Monitoring Protocol
Recommended follow-up and surveillance
High-Dose Folate & Targeted Ultrasound
  • Prescribe high-dose folic acid (4-5 mg/day)
  • Level II targeted ultrasound for neural tube defects at 18-22 weeks
Safer Alternatives
Active ingredients with better pregnancy safety profiles
lamotrigine
First-line safer anticonvulsant in pregnancy.
Safer Alternative
levetiracetam
First-line safer anticonvulsant in pregnancy.
Safer Alternative
Professional Clinical Notes
Key prescribing considerations and clinical pearls
  • FDA Black Box Warning regarding valproate neurodevelopmental risks.
Patient-Friendly Explanation
In simple, easy-to-understand language
Easy to Understand

Valproic acid (Depakote) is not safe during pregnancy because it increases the risk of spina bifida and lowers child IQ. Talk to your neurologist to switch to a safer medication like lamotrigine.

Frequently Asked Questions
Common questions about Valproic Acid in pregnancy

Valproic acid causes neural tube defects (spina bifida) and lowers IQ in children exposed in the womb.

Evidence Level
Quality of available safety data
FDA Category D/X & Black Box Warning

FDA Black Box Warning & European Medicines Agency (EMA) contraindications.

References & Primary Sources
Official U.S. Food & Drug Administration (FDA) PLLR & ACOG Clinical Database
All pregnancy safety evaluations, risk categories, and drug monographs are compiled directly from U.S. FDA Pregnancy and Lactation Labeling Rule (PLLR) standards and approved FDA prescribing labels.
  1. 1
    U.S. Food and Drug Administration (FDA) PLLR — FDA Pregnancy and Lactation Labeling Rule & Approved Prescribing Information Database Last updated: Official FDA Standard
  2. 2
    FDA Center for Drug Evaluation and Research (CDER) — FDA MedWatch & Black Box Warning Database Last updated: Official FDA Standard
  3. 3
    ACOG Practice Bulletins & Guidelines — American College of Obstetricians and Gynecologists Clinical Recommendations Last updated: 2025 Clinical Edition
  4. 4
    Briggs Drugs in Pregnancy and Lactation — Reference Guide to Fetal and Neonatal Risk (12th Edition) Last updated: 2025 Clinical Edition
Search Another Medication

System Notice

Confirm Action